Caris Life Sciences (CAI) Stock Advances +16.7% in 30 Days on Strong Execution
Key Takeaways
- CAI shares advanced roughly 16.7% over the last 30 days, from about $26.27 to $30.65, extending a broader multi-month rally.
- The move reflects follow-through from record second-quarter 2026 results, including 45% year-over-year revenue growth and a raised full-year outlook.
- Expanding gross margin, positive adjusted EBITDA, and a fifth consecutive quarter of positive free cash flow reinforced the growth narrative.
- Product catalysts, led by the Caris Detect multi-cancer early-detection launch, supported the company's AI-driven TechBio positioning.
- Over the trailing three months, the stock has gained more than 60%.
Caris Life Sciences (CAI) Company Overview and Market Position
Caris Life Sciences is a precision medicine and artificial intelligence "TechBio" company headquartered in Irving, Texas. The company develops and commercializes comprehensive molecular profiling services built on whole genome, whole exome, and whole transcriptome sequencing, combined with advanced AI and machine learning. Its portfolio includes the MI Profile tissue-based platform, the Caris Assure blood-based assay, the ChromoSeq hematology profiling test, and Caris Detect, a multi-cancer early-detection blood test, as well as pharma research and development services. With more than 1.13 million profiled patients and a large multimodal clinico-genomic database, CAI has positioned itself as a scaled player in precision oncology, competing on the depth and comprehensiveness of its testing and the proprietary data underpinning its AI models. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Caris Life Sciences (CAI) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CAI rose from a closing price of approximately $26.27 to $30.65, a gain of about 16.7%. The shares advanced through late August, consolidated modestly in early September, and then pushed to multi-month highs in mid-September amid sustained buying interest.
The quarterly trend has been even stronger. From roughly $18.50 in late June, the stock climbed more than 60% to its current level, marking a clear uptrend characterized by higher highs and higher lows. This multi-month advance places the stock well above its spring 2026 lows, though still below its 52-week high.
What Drove CAI Stock Price in the Last 30 Days
The dominant catalyst behind CAI's recent strength was its second-quarter 2026 earnings report released in early August. The company reported total revenue of $263.7 million, up 45% year over year, driven by 55% growth in molecular profiling services revenue. Gross margin expanded to 68%, up from 63% a year earlier, while net loss narrowed to $0.6 million. Adjusted EBITDA reached $55.7 million, and the company generated $6.4 million in free cash flow, its fifth consecutive quarter of positive free cash flow. Management also raised full-year 2026 revenue guidance to a range of $1.03 billion to $1.04 billion, implying 27% to 28% growth.
Beyond the headline numbers, investor enthusiasm centered on the launch of Caris Detect, a multi-cancer early-detection blood test covering 58 cancer types, and the commercial momentum in clinical case volume, which rose to roughly 59,200 cases. The company's AI-driven platform narrative, including its large language model-based assistant, reinforced its positioning within the broader AI-in-healthcare theme that has attracted strong investor attention. A share repurchase authorization of up to $100 million also signaled management's confidence in the stock. From what I see, the combination of financial improvement and product momentum has been key here.
What Drove CAI Stock Performance Over the Last Quarter
The larger quarterly advance was shaped by a sequence of company-specific milestones. In June, Caris launched Caris Detect, announced a dual listing on NYSE Texas, and authorized its share repurchase program. These events were followed by the August earnings report, which demonstrated accelerating revenue, improving profitability, and strong cash generation. The company also expanded its Precision Oncology Alliance to 101 members, adding institutions such as UC San Francisco and Northwell Health, and received MolDX approval for its ChromoSeq assay. Together, these developments reinforced a narrative of commercial execution, expanding test menu, and progress toward an MRD (minimal residual disease) launch, supporting the stock's sustained upward trajectory over the quarter.
CAI Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to influence CAI's trajectory. The company's next quarterly earnings report is expected in early November, and investors will focus on whether clinical case volume, average selling prices, and margin expansion continue on their current path. The anticipated launch of an MRD assay in the second half of 2026 represents a key pipeline milestone. The commercial ramp of Caris Detect will also be closely watched, particularly given management's acknowledgment of potential capacity constraints and the test's current self-pay reimbursement status. Additional items include the pending New York State approval process for the Caris Assure blood-based assay, evolving payer coverage decisions, and the broader competitive landscape in liquid biopsy and precision oncology. As with any high-growth healthcare company, execution against guidance and reimbursement dynamics remain central risks to monitor. I’m watching this closely as the next few quarters unfold.
Using Tickeron Tools in My Analysis
In reviewing names like this one, I often turn to Tickeron’s Trending AI Robots page to explore automated strategies across various timeframes. It offers a curated view of top-performing bots that can help simulate different approaches on securities such as CAI, providing additional perspective alongside traditional research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CAI sees its Stochastic Oscillator climbs out of oversold territory
On October 09, 2026, the Stochastic Oscillator for CAI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 16 instances where the indicator left the oversold zone. In 13 of the 16 cases the stock moved higher in the following days. This puts the odds of a move higher at over 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on CAI as a result. In 19 of 30 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
Following a +7.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAI advanced for three days, in 45 of 65 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
CAI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 23 of 53 cases where CAI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 43%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAI moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 7 similar instances where the indicator moved out of overbought territory. In 4 of the 7 cases, the stock moved lower in the following days. This puts the odds of a move lower at 57%.
The Moving Average Convergence Divergence Histogram (MACD) for CAI turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In 5 of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.152) is normal, around the industry mean (26.782). P/E Ratio (3.316) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (9.059). CAI's Dividend Yield (0.021) is considerably higher than the industry average of (0.000). P/S Ratio (8.084) is also within normal values, averaging (437.542).
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. CAI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in the business of leasing international intermodal marine cargo containers
Industry Biotechnology
Advertisement